Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

BAXTER HEALTHCARE SA

Home Clinical Trial Sponsors and OrganizationsBAXTER HEALTHCARE SA

BAXTER HEALTHCARE SA

BLOCK 2, Blackrock, Ireland

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

3

3 active

Approvals

2

Total approvals

Agencies

1

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

2

66.7%

Trial Status Distribution

Active, not recruiting

3

100.0%

Clinical Trials

Trials sponsored by this organization (3)

Efficacy and Safety of Epoetin-Omega i.v. for Treatment of Anemia in Hemodialyzed Patients Hyporesponsive to a Previous Epoetin Beta i.v. Treatment: a Randomized, Parallel Group Trial. - Epomax Hyporesponsive patients study

Active, not recruiting

Oct 200446 participants

An Evaluation of the Efficacy of Epo-Omega in Treatment of Anaemia in ESRD Patients When Administered by Thrice Weekly Intravenous Injection: A Dose Dependency Evaluation. - Epomax (3 x week i.v.) A dose dependency evaluatio

Active, not recruiting

An Evaluation of the Efficacy of Epo-Omega in The Treatment of Anaemia in Chronic Kidney Disease (CKD) Patients When Administered by Once Weekly Subcutaneous Injection: A Dose Dependency Evaluation. - Epomax (1 x / week s.c.) A dose dependency evaluatio

Active, not recruiting

Aug 2004105 participants

Approvals

Approvals by Agency

SFDA

Saudi Food and Drug Authority

2

Approvals

Recent Approvals

NUTRYELT CONC. FOR SOLUTION FOR INFUSION

News

No news articles found

On this page

Overview
Clinical Trials3
Approvals2
News

Back to Organizations